Collaboration and License Agreements (Tables)

9 Months Ended

Sep. 30, 2015

Collaboration and License Agreements

Schedules of tables providing amounts included in the company's consolidated statement of comprehensive (loss) income attributable to transactions arising from its collaborative arrangements

	For the Three Months Ended September 30, 2015 (in thousands)
	2003 Sandoz Collaboration		2006 Sandoz Collaboration		Baxalta Agreement		Total Collaborations
Collaboration revenues:
Product revenue	$	—	$	8,666	$	—	$	8,666
Research and development revenue:
Regulatory and commercial milestones	—		—		—		—
Amortization of upfront payments	—		—		2,442		2,442
Research and development services (FTEs) and external costs	69		742		1,876		2,687
Total research and development revenue	$	69	$	742	$	4,318	$	5,129
Total collaboration revenues	$	69	$	9,408	$	4,318	$	13,795
Operating expenses:
Research and development expense (1)	$	—	$	274	$	251	$	525
General and administrative expense (1)	$	104	$	38	$	166	$	308
Total operating expenses	$	104	$	312	$	417	$	833

	For the Three Months Ended September 30, 2014 (in thousands)
	2003 Sandoz Collaboration		2006 Sandoz Collaboration		Baxalta Agreement		Total Collaborations
Collaboration revenues:
Product revenue	$	4,714	$	—	$	—	$	4,714
Research and development revenue:
Amortization of upfront payments	—		121		767		888
Research and development services (FTEs) and external costs	195		944		2,595		3,734
Total research and development revenue	$	195	$	1,065	$	3,362	$	4,622
Total collaboration revenues	$	4,909	$	1,065	$	3,362	$	9,336
Operating expenses:
Research and development expense (1)	$	50	$	444	$	3,639	$	4,133
General and administrative expense (1)	$	15	$	84	$	242	$	341
Total operating expenses	$	65	$	528	$	3,881	$	4,474

	For the Nine Months Ended September 30, 2015 (in thousands)
	2003 Sandoz Collaboration		2006 Sandoz Collaboration		Baxalta Agreement		Total Collaborations
Collaboration revenues:
Product revenue	$	2,843	$	27,850	$	—	$	30,693
Research and development revenue:
Regulatory and commercial milestones	—		20,000		—		20,000
Amortization of upfront payments	—		—		6,572		6,572
Research and development services (FTEs) and external costs	450		2,220		7,323		9,993
Total research and development revenue	$	450	$	22,220	$	13,895	$	36,565
Total collaboration revenues	$	3,293	$	50,070	$	13,895	$	67,258
Operating expenses:
Research and development expense (1)	$	208	$	703	$	1,376	$	2,287
General and administrative expense (1)	$	326	$	149	$	798	$	1,273
Total operating expenses	$	534	$	852	$	2,174	$	3,560

	For the Nine Months Ended September 30, 2014 (in thousands)
	2003 Sandoz Collaboration		2006 Sandoz Collaboration		Baxalta Agreement		Total Collaborations
Collaboration revenues:
Product revenue	$	15,216	$	—	$	—	$	15,216
Research and development revenue:
Amortization of upfront payments	—		480		2,309		2,789
Research and development services (FTEs) and external costs	796		1,738		10,532		13,066
Total research and development revenue	$	796	$	2,218	$	12,841	$	15,855
Total collaboration revenues	$	16,012	$	2,218	$	12,841	$	31,071
Operating expenses:
Research and development expense (1)	$	134	$	973	$	11,868	$	12,975
General and administrative expense (1)	$	110	$	315	$	399	$	824
Total operating expenses	$	244	$	1,288	$	12,267	$	13,799

(1) The amounts represent external expenditures, including amortization of an intangible asset, and exclude salaries and benefits, share-based compensation, facilities, depreciation and laboratory supplies, as these costs are not directly charged to programs.